文献速递妇产影像技术与安全

母体N末端B型利钠肽原对子痫前期孕妇严重母体不良结局的预测价值

Prognostic value of maternal N-terminal pro-B-type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-11-08

本回顾性队列研究纳入130例妊娠≤36周确诊子痫前期的单胎孕妇,检测确诊时母体血清NT-proBNP、sFlt-1与PlGF水平。13例(10%)发生严重母体不良结局,该组NT-proBNP中位数显著更高(688.0 pg/mL vs 106.1 pg/mL,P<0.001)。校正采样孕周及sFlt-1/PlGF比值Z评分后,NT-proBNP Z评分与严重母体不良结局显著相关(校正OR 3.24,95%CI 1.50-7.84;P=0.005),并可预测更短的至分娩时间(校正HR 3.08,95%CI 1.47-6.44;P=0.003)。ROC分析显示NT-proBNP判别能力优于sFlt-1/PlGF比值(AUC 0.75 vs 0.67),联合采样孕周后两者AUC分别提高至0.82与0.76。作者认为NT-proBNP是严重母体不良结局及至分娩时间的强预测因子,尤其在早发型病例中,可能作为已确诊子痫前期孕妇风险分层与监测的临床可及生物标志物。

要点

  • 确诊子痫前期时NT-proBNP升高与严重母体不良结局风险增加相关(校正OR 3.24,95%CI 1.50-7.84)。
  • NT-proBNP对严重母体不良结局的判别能力优于sFlt-1/PlGF比值(AUC 0.75 vs 0.67)。
  • 联合采样孕周可提高两种生物标志物的判别能力(AUC 0.82 vs 0.76)。

核心结论

  • 在确诊子痫前期的孕妇中,NT-proBNP是严重母体不良结局及至分娩时间的强预测因子,尤其在早发型病例中;NT-proBNP可能作为已确诊子痫前期孕妇风险分层与监测的临床可及生物标志物。

研究设计与样本

  • 回顾性队列研究,纳入2018年1月至2023年12月在维也纳医科大学评估的妊娠≤36周确诊子痫前期的单胎孕妇130例,检测确诊时母体血清NT-proBNP、sFlt-1与PlGF水平;主要结局为严重母体不良事件(包括重症监护室入住、母体死亡、肺水肿和严重神经系统并发症)。

诊断标准与关键数值

  • 严重母体不良结局组NT-proBNP中位数688.0 pg/mL(IQR 249.6-1038.0)vs 无严重母体不良结局组106.1 pg/mL(IQR 50.6-280.6),P<0.001;NT-proBNP Z评分与严重母体不良结局的校正OR 3.24(95%CI 1.50-7.84),P=0.005;与至分娩时间的校正HR 3.08(95%CI 1.47-6.44),P=0.003;NT-proBNP预测严重母体不良结局的AUC 0.75(95%CI 0.61-0.90),sFlt-1/PlGF比值AUC 0.67(95%CI 0.56-0.79);联合采样孕周后NT-proBNP AUC 0.82(95%CI 0.71-0.94),sFlt-1/PlGF比值AUC 0.76(95%CI 0.65-0.88)。

临床应用与阅片要点

  • 作者认为NT-proBNP可能作为已确诊子痫前期孕妇风险分层与监测的临床可及生物标志物,尤其在早发型病例中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: N-terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of cardiac stress, has been proposed as a potential prognostic biomarker for maternal adverse outcome in pre-eclampsia (PE). This study aimed to evaluate the predictive value of NT-proBNP for severe maternal adverse outcome in pregnancies with an established diagnosis of PE.

METHODS: This was a retrospective cohort study of singleton pregnancies diagnosed with PE ≤ 36 weeks of gestation that were assessed at the Medical University of Vienna between January 2018 and December 2023. Maternal serum levels of NT-proBNP, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) were measured at the time of PE diagnosis. The primary outcome was the occurrence of a severe maternal adverse event, including intensive care unit admission, maternal death, pulmonary edema and severe neurological complications. Associations between severe maternal adverse outcome and Z-scores for NT-proBNP and the sFlt-1/PlGF ratio were analyzed using logistic and Cox regression models adjusted for gestational age at sampling and the Z-score of the other biomarker. The area under the receiver-operating-characteristics (ROC) curve (AUC) was used to assess the discriminative ability of the biomarkers.

RESULTS: Of 130 women included in our cohort, 13 (10%) experienced severe maternal adverse outcome. NT-proBNP levels were significantly higher in this group (median, 688.0 (interquartile range (IQR), 249.6-1038.0) pg/mL vs 106.1 (IQR, 50.6-280.6) pg/mL; P < 0.001). Higher NT-proBNP Z-score was associated significantly with severe maternal adverse outcome (adjusted odds ratio, 3.24 (95% CI, 1.50-7.84); P = 0.005) and predicted shorter time-to-delivery with severe maternal adverse outcome (adjusted hazard ratio, 3.08 (95% CI, 1.47-6.44); P = 0.003) after adjusting for gestational age at sampling and sFlt-1/PlGF ratio Z-score. The sFlt-1/PlGF ratio was not associated significantly with these outcomes. ROC-curve analysis showed that NT-proBNP had superior discriminative performance compared with the sFlt-1/PlGF ratio (AUC, 0.75 (95% CI, 0.61-0.90) vs 0.67 (95% CI, 0.56-0.79)). The performance of both biomarkers improved when combined with gestational age at sampling (AUC, 0.82 (95% CI, 0.71-0.94) vs 0.76 (95% CI, 0.65-0.88)).

CONCLUSION: NT-proBNP was a strong predictor of severe maternal adverse outcome and time-to-delivery in women diagnosed with PE, especially in early-onset cases. NT-proBNP may serve as a clinically accessible biomarker for risk stratification and surveillance in women with established PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Palmrich P, Kalafat E, Schirwani-Hartl N, et al. Prognostic value of maternal N-terminal pro-B-type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre-eclampsia. Ultrasound Obstet Gynecol. 2025. PMID: 41206530. doi:10.1002/uog.70129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。